Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Dossier - 13/04/2015 In Germany, young girls can now protect themselves from cervical cancer. (Photo: NCI)

    Boosting the immune system can improve cancer prevention and treatment

    The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/boosting-the-immune-system-can-improve-cancer-prevention-and-treatment
  • Article - 16/03/2015 22977_de.jpg

    Heike Brötz-Oesterhelt - searching for novel antibiotics in bacteria

    Microbial metabolic products can be used in the fight against dangerous pathogens such as multidrug-resistant bacteria. Since summer 2014, microbiologist Prof. Dr. Heike Brötz-Oesterhelt has been investigating the mechanisms of action of bacterial substances at the University of Tübingen with the aim of paving the way for new antibiotics. Interesting candidates have already been identified.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heike-broetz-oesterhelt-searching-for-novel-antibiotics-in-bacteria
  • Article - 09/03/2015 22905_de.jpg

    Treating cancer by activating the immune system

    Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/treating-cancer-by-activating-the-immune-system
  • Press release - 06/03/2015 07777_de.jpg

    The Bill & Melinda Gates Foundation invests €46 million in CureVac

    The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest €46 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA platform. In addition, CureVac’s…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-bill-melinda-gates-foundation-invests-46-million-in-curevac
  • Article - 16/02/2015 22810_de.jpg

    Therapeutic vaccines against brain tumours

    Therapeutic cancer vaccines have the potential to boost the immune system's ability to destroy tumour cells. Cancer researchers around the world are intensively studying the potential of this therapeutic concept and initial positive results have been obtained. Cancer researchers from Heidelberg have developed a vaccine that triggers an immune response against a protein that is mutated in brain cancer. The vaccine, which successfully arrested…

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-vaccines-against-brain-tumours
  • Article - 26/01/2015 Photo showing a laboratory involved in the TTU "Malaria". The photo shows two scientists working at a work bench.

    Pooling efforts against infectious diseases in Germany

    Over 150 scientists at various locations throughout Germany work together as part of the German Centre for Infection Research (DZIF). The centre focuses on the development of new diagnostic, preventive and therapeutic methods for treating infectious diseases. Scientists from the University and University Hospital of Tübingen and the Max Planck Institute for Developmental Biology are also part of the project. The researchers from Tübingen are…

    https://www.gesundheitsindustrie-bw.de/en/article/news/pooling-efforts-against-infectious-diseases-in-germany
  • Article - 22/12/2014 22598_de.jpg

    Fighting hepatitis viruses with their own weapons

    Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…

    https://www.gesundheitsindustrie-bw.de/en/article/news/fighting-hepatitis-viruses-with-their-own-weapons
  • Article - 20/10/2014 22216_de.jpg

    Michael Schindler: HI virus and host interactions

    Prof. Dr. Michael Schindler explores the interaction between viruses and their human host cells on the molecular level. His specific interest is HI virus infections and the mechanisms the virus uses to attack the human immune system. Schindler’s eventual aim is to identify a new target for the therapy of HIV infections. In April 2014, Schindler was appointed head of the Department of Molecular Virology of Human Infectious Diseases at the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/michael-schindler-hi-virus-and-host-interactions
  • Article - 18/08/2014 The photo shows 7 staff members of VAXIMM GmbH.

    VAXIMM: Vaccines that impede cancer growth

    VAXIMM GmbH, a young biotechnology company from Mannheim, Germany, specialises in the development of vaccines for cancer treatment. The company’s first product candidate, VXM01, is a live oral vaccine that targets the VEGFR-2 receptor and hence the blood supply of tumours. VXM01 is currently undergoing clinical testing in pancreatic cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaximm-vaccines-that-impede-cancer-growth
  • Dossier - 31/03/2014 Teaser_adrenomedullin_WikimediaImages_pixabay_g566109ad4_1920.jpg

    Peptides – diverse molecules of life

    Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Despite some drawbacks, peptides are gaining in importance as candidates for drugs…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
  • Article - 24/03/2014 Section of a malignant skin tumour in Mastomys coucha. Dividing tumour cells are stained red.

    Vaccine against papillomaviruses protects from skin cancer

    Papillomaviruses are thought to cause non-melanoma skin cancer in people exposed to UV radiation, especially those who have suppressed immune systems. Researchers from the German Cancer Research Center (DKFZ) and the Charité University Hospital in Berlin have developed a vaccine that protects mice against such skin tumours. The vaccine is even effective in mice that have previously been infected with papillomaviruses and that have suppressed…

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccine-against-papillomaviruses-protects-from-skin-cancer
  • Press release - 11/03/2014 CureVac's new cancer vaccine is based on modified mRNA molecules

    CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize

    10 March 2014 CureVac a German clinical stage biopharmaceutical company today announced that it has won the inaugural European Commission Vaccine Prize. The EU has dedicated the prize of two million Euros in an effort to stimulate innovative solutions for vaccine transportation and storage where cold chain cannot be guaranteed. CureVacs RNActive vaccine technology based on messenger RNA mRNA convinced the panel of judges of its potential as a…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-wins-two-million-eur-from-inaugural-european-commission-vaccine-prize
  • Article - 27/01/2014 Discovery team members checking the settings of a mass spectrometer.

    immatics biotechnologies GmbH: active against cancer

    immatics biotechnologies GmbH is a biopharmaceutical company wholly concerned with the development of advanced immunotherapies that are active against different types of cancer, including renal cell, colorectal, brain and gastric cancer. The company currently has a workforce of 80 at its headquarters in Tübingen and subsidiary in Munich. It capitalises on the know-how in the analysis of tumour cells and vaccine development gained through its…

    https://www.gesundheitsindustrie-bw.de/en/article/news/immatics-biotechnologies-gmbh-active-against-cancer
  • Article - 20/01/2014 The photo shows a small metal device with wires and standing in a mount.

    Microarray copier – for copying DNA, RNA and protein arrays

    Dr. Günter Roth from the Centre for Biological Systems Analysis at the University of Freiburg is working on the development of a microarray copier that can almost at the push of a button copy arrays of any type of molecule DNA RNA and proteins from next-generation sequencing chips onto standard slides thereby combining the world of microarrays with the sequencing world. The approach has a huge application potential for the production of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/microarray-copier-for-copying-dna-rna-and-protein-arrays
  • Press release - 15/10/2013 Immatics Logo

    Biotech financing in Baden-Württemberg: immatics raises 34 million Euros

    The immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a 34 million Euros Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biotech-financing-in-baden-wuerttemberg-immatics-raises-34-million-euros
  • Article - 30/09/2013 Person holding a vial with vaccine.

    CureVac GmbH: RNA-based vaccines and immunotherapies

    CureVac GmbH, a biopharmaceutical company based in Tübingen, develops immunotherapies for cancer along with prophylactic vaccines based on its proprietary messenger RNA (mRNA) technology platform. CureVac also uses RNA for developing adjuvants. Two clinical trials, a Phase I trial in non-small cell lung cancer (NSCLC) and a Phase IIb trial in prostate cancer, are currently underway to test the efficiency of mRNA-based drugs in treating cancer and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-gmbh-rna-based-vaccines-and-immunotherapies
  • Article - 08/07/2013 19802_de.jpg

    Christine Goffinet: independent and successful AIDS researchers

    Christine Goffinet, 36, from the Institute of Molecular Virology at the University of Ulm has already received numerous awards for her research on AIDS. She was recently awarded a scholarship for postdoctoral lecture qualification under the Margarete von Wrangell Habilitation Programme. However, before she became a virologist, Goffinet chose a career path that was quite different from the standard career path seen on many scientific CVs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/christine-goffinet-independent-and-successful-aids-researchers
  • Article - 17/05/2013 19602_de.jpg

    Dengue fever, the neglected infectious disease

    Dengue fever is the most common infectious disease transmitted by mosquitoes. The disease is spreading in Europe and Germany, an upward trend that is due to increased long-distance travel. There are no specific drugs or vaccine for dengue, which is why an international research network has been established to improve the management of the disease. The consortium is coordinated by the Department of Tropical Medicine at Heidelberg University.

    https://www.gesundheitsindustrie-bw.de/en/article/news/dengue-fever-the-neglected-infectious-disease
  • Press release - 30/04/2013 19630_de.jpg

    Impressions from the 2013 BIO International Convention in Chicago

    A trade fair turns 20 and an industrial sector is coming of age. Where does BIO stand today? The number of exhibitors has slightly decreased the conference is characterised by general themes and trends and partnering has become the most important and indispensable part of the global event for biotechnology. What was once a gold rush atmosphere has given way to an experienced self-confidence about the economic importance of biotechnology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/impressions-from-the-2013-bio-international-convention-in-chicago
  • Dossier - 01/04/2013 19423_de.jpg

    Retroviruses: from infectious agent to therapeutic assistant

    Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. Despite some similarities with accepted forms of life viruses are not considered as such. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV which leads to AIDS and for which no cure or effective vaccine is currently available. However retroviruses are not only of…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
  • Article - 04/02/2013 19136_de.jpg

    G protein-coupled receptors and their importance for research and development

    Brian Kobilka and Robert Lefkowitz were awarded the 2012 Nobel Prize in Chemistry for their groundbreaking discoveries of the inner workings of G protein-coupled receptors (GPCRs). These transmembrane receptors play a key role in the processing of odours and the recognition of hormones. The work of the two American scientists has had an impact on many researchers around the world. In the following interview, Professor Dr. Daniel Legler, head of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/g-protein-coupled-receptors-and-their-importance-for-research-and-development
  • Press release - 13/11/2012 18685_de.jpg

    immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment

    immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment
  • Press release - 12/11/2012 Immatics Logo

    immatics appoints Peter Chambré as Chairman

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-peter-chambr-as-chairman
  • Press release - 30/10/2012 Logo DKFZ, blue letters "DKFZ"

    DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine

    Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
  • Article - 15/10/2012 18369_de.jpg

    gerbion®: hunting down pathogens

    Detecting viruses, bacteria or parasites in human, animal, food and environmental samples is routine for the staff of gerbion GmbH & Co. KG. The company has been using virological, microbiological and serological methods for many years, but is now also using cutting-edge molecular biology methods for detecting pathogens. The founders of the Kornwestheim-based diagnostics company have concentrated on own research work and the development of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/gerbion-hunting-down-pathogens

Page 5 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search